Sanara's 15-minute chart triggered a bullish KDJ Golden Cross and Marubozu formation.

According to Sanara's 15-minute chart, a KDJ Golden Cross and Bullish Marubozu occurred on November 9, 2025, at 09:45. This indicates a shift in the momentum of the stock price towards an upward trend, suggesting that the stock has the potential to further increase in value. The presence of buyers controlling the market suggests that bullish momentum is likely to continue.

Sanara MedTech Inc. (NASDAQ: SMTI) has been making strategic moves to balance aggressive growth with prudent debt management. The company recently secured a $55M non-dilutive loan to fund its Surgical segment growth and Tissue Health Plus (THP) platform development, aiming to preserve shareholder value while increasing debt to $43.4M Sanara MedTech’s Strategic Debt Management and the Path to Sustainable Growth^[1].

In Q2 2025, Sanara reported a 28% revenue growth to $25.8M, with the Surgical segment achieving a 93% gross margin and a $0.5M net profit. Despite a $2.5M loss in the THP segment, the company demonstrated operational efficiency and profitability turnaround Sanara MedTech’s Strategic Debt Management and the Path to Sustainable Growth^[1]. The appointment of a new CEO from within the company’s commercial operations further indicates a focus on growth and profitability in the Surgical segment Sanara MedTech: Growth Remains Strong As Debt Concerns Recede^[2].

Sanara's debt-to-EBITDA ratio, while elevated, is not unprecedented in the medtech sector. The company's ability to generate consistent cash flow from its Surgical segment provides a buffer against refinancing risks. Moreover, its focus on expanding its distribution network and increasing facility penetration in U.S. markets offers a scalable path to growth Sanara MedTech’s Strategic Debt Management and the Path to Sustainable Growth^[1].

The recent appointment of a new CEO and the strategic review of the THP segment are significant developments. The company plans to cap further spending on THP at $6 million, ensuring significant free cash flow (FCF) in the next year Sanara MedTech: Growth Remains Strong As Debt Concerns Recede^[2]. This strategic move addresses the concerns related to the significant debt on the balance sheet and positions Sanara to return to strong FCF generation.

Market analysts have noted that Sanara's stock has shown strong momentum, with a KDJ Golden Cross and Bullish Marubozu occurring on November 9, 2025, at 09:45. This indicates a shift in the momentum of the stock price towards an upward trend, suggesting that the stock has the potential to further increase in value .

For investors, Sanara MedTech represents a compelling case study in strategic debt management. By aligning its capital structure with long-term growth objectives, the company is positioning itself to thrive in a competitive industry. The coming quarters will test whether its balance of ambition and prudence can translate into sustained value creation.